Page 111 - Read Online

Samaha et al. Hyperlipidemia in Lebanon

patient education as well as national programs be put cholesterol and cardiovascular disease. Four prospective American
in place to further reduce the major risk factors of CVD. studies. Circulation 1989;79:8-15.
6. Musunuru K, Kathiresan S. Surprises from genetic analyses of lipid
DECLARATIONS 7. risk factors for atherosclerosis. Circ Res 2016;118:579-85.
Daugherty A, Tabas I, Rader DJ. Accelerating the pace of
atherosclerosis research. Arterioscler Thromb Vasc Biol
Authors’ contributions 2015;35:11-2.
Contributed to the collection of data: A.A. Samaha, 8. Melendez QM, Krishnaji ST, Wooten CJ, Lopez D.
M. Gebbawi, M. Fawaz, R. Houjayri, R. Samaha, S. Hypercholesterolemia: the role of PCSK9. Arch Biochem Biophys
Baydoun 2017;625-626:39-53.
Analyzed the results: A.H. Eid, F. Zouein 9. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha
MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C,
Wrote the manuscript: A.H. Eid Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela
BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey
Acknowledgments RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK,
The authors would like to thank all those who helped Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G,
in dealing with the patients, specimen collection, etc. Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A,
for their assistance. Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart
Association Statistics Committee and Stroke Statistics Subcommittee.
Financial support and sponsorship Heart disease and stroke statistics--2014 update: a report from the
American Heart Association. Circulation 2014;129:e28-e292.
None. 10. Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S.
Epidemiology of atherosclerosis and the potential to reduce the global
Conflicts of interest burden of atherothrombotic disease. Circ Res 2016;118:535-46.
There are no conflicts of interest. 11. Saleh Al-Shehabi T, Iratni R, Eid AH. Anti-atherosclerotic plants
which modulate the phenotype of vascular smooth muscle cells.
Patient consent Phytomedicine 2016;23:1068-81.
Informed consent was obtained for all participants, 12. World Health Organization. World Health Report 2002. Available from:
either directly (for those 18 years or older) or through http://www.who.int/whr/2002/en/. [Last accessed on Jul 31, 2017]
the parents/legal guardians (for subjects under 18 13. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko
HR, Williams PT, Johnstone IM, Champagne MA, Krauss RM. Effects
years of age). of intensive multiple risk factor reduction on coronary atherosclerosis
and clinical cardiac events in men and women with coronary artery
Ethics approval disease. The Stanford Coronary Risk Intervention Project (SCRIP).
The protocols followed for data collection, handling, Circulation 1994;89:975-90.
and analyzing were approved by the Research Ethics 14. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT,
Committee at the Lebanese University and Makassed Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating
General Hospital. Committee of the National Cholesterol Education Program.
Implications of recent clinical trials for the National Cholesterol
Education Program Adult Treatment Panel III Guidelines. J Am Coll
REFERENCES Cardiol 2004;44:720-32.
15. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere
1. World Health Organization. Cardiovascular diseases (CVDs). In: Fact PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary
Sheets: World Health Organization; 2017. prevention of acute coronary events with lovastatin in men and women
2. Wilson P, D’Agostino R, Levy D, Belanger A, Silbershatz H, Kannel with average cholesterol levels: results of AFCAPS/TexCAPS. Air
W. Prediction of coronary heart disease using risk factor categories. Force/Texas Coronary Atherosclerosis Prevention Study. JAMA
Circulation 1998;97:1837-47. 1998;279:1615-22.
3. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, 16. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD,
Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR,
JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Braunwald E. The effect of pravastatin on coronary events after
Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, Watts GF; myocardial infarction in patients with average cholesterol levels.
European Atherosclerosis Society Consensus Panel. Triglyceride- Cholesterol and Recurrent Events Trial investigators. N Engl J Med
rich lipoproteins and high-density lipoprotein cholesterol in patients 1996;335:1001-9.
at high risk of cardiovascular disease: evidence and guidance for 17. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman
management. Eur Heart J 2011;32:1345-61. G, Pyörälä K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel H;
4. National Cholesterol Education Program (NCEP) Expert Panel on Scandinavian Simvastatin Survival Study Group. Randomised trial
Detection E, and Treatment of High Blood Cholesterol in Adults of cholesterol lowering in 4444 patients with coronary heart disease:
(Adult Treatment Panel III). Third Report of the National Cholesterol the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler
Education Program (NCEP) Expert Panel on Detection, Evaluation, Suppl 2004;5:81-7.
and Treatment of High Blood Cholesterol in Adults (Adult Treatment 18. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons
Panel III) final report. Circulation 2002;106:3143-421. from sudden coronary death: a comprehensive morphological
5. Gordon D, Probstfield J, Garrison R, Neaton J, Castelli W, Knoke classification scheme for atherosclerotic lesions. Arterioscler Thromb
J, Jacobs DJ, Bangdiwala S, Tyroler H. High-density lipoprotein Vasc Biol 2000;20:1262-75.
104 Vessel Plus ¦ Volume 1 ¦ September 26, 2017